Junyu Long

List of Publications by Year
in descending order

55 papers	1,686 citations	430754 18 h-index	345118 36 g-index
57 all docs	57 docs citations	57 times ranked	1882 citing authors

#	Article	IF	Citations
1	Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine, 2019, 42, 363-374.	2.7	257
2	A four‑gene‑based prognostic model predicts overall survival in patients with hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2018, 22, 5928-5938.	1.6	128
3	Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression. Journal of Cellular Physiology, 2019, 234, 18837-18848.	2.0	103
4	Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. , 2021, 9, e003334.		101
5	DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics, 2019, 9, 7251-7267.	4.6	99
6	Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surgery and Nutrition, 2020, 9, 414-424.	0.7	93
7	Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma. Cancer Cell International, 2019, 19, 90.	1.8	90
8	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. Journal of Hematology and Oncology, 2017, 10, 146.	6.9	77
9	Alterations in DNA Damage Repair Genes in Primary Liver Cancer. Clinical Cancer Research, 2019, 25, 4701-4711.	3.2	74
10	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. Journal of Hematology and Oncology, 2019, 12, 42.	6.9	58
11	Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysis. Briefings in Bioinformatics, 2021, 22, .	3.2	46
12	Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Differentially Expressed Genes. International Journal of Biological Sciences, 2020, 16, 1153-1165.	2.6	45
13	Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. BMC Cancer, 2018, 18, 766.	1.1	42
14	Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics, 2021, 11, 4585-4598.	4.6	39
15	Construction and Investigation of a lncRNA-Associated ceRNA Regulatory Network in Cholangiocarcinoma. Frontiers in Oncology, 2019, 9, 649.	1.3	32
16	Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. BMC Medicine, 2021, 19, 154.	2.3	32
17	Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. Hepatobiliary Surgery and Nutrition, 2021, 10, 434-442.	0.7	28
18	CeRNA regulatory network-based analysis to study the roles of noncoding RNAs in the pathogenesis of intrahepatic cholangiocellular carcinoma. Aging, 2020, 12, 1047-1086.	1.4	27

#	Article	IF	Citations
19	A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. Genome Medicine, 2022, 14, 20.	3.6	26
20	Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice. Annals of Translational Medicine, 2019, 7, 467-467.	0.7	24
21	The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study. Frontiers in Oncology, 2021, 11, 646979.	1.3	23
22	Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. , 2021, 9, e001942.		22
23	Dyslipidemia Might Be Associated with an Increased Risk of Osteoarthritis. BioMed Research International, 2020, 2020, 1-9.	0.9	20
24	Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma. International Immunopharmacology, 2020, 89, 107135.	1.7	17
25	Transcriptomic analysis and identification of prognostic biomarkers in cholangiocarcinoma. Oncology Reports, 2019, 42, 1833-1842.	1.2	16
26	The diagnostic and prognostic role of RhoA in hepatocellular carcinoma. Aging, 2019, 11, 5158-5172.	1.4	16
27	Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer. Cancers, 2021, 13, 3343.	1.7	14
28	Metabolic syndrome and the risk of cholangiocarcinoma: a hospital-based case&ndash;control study in China. Cancer Management and Research, 2018, Volume 10, 3849-3855.	0.9	13
29	Systematic review and meta-analysis: cholecystectomy and the risk of cholangiocarcinoma. Oncotarget, 2017, 8, 59648-59657.	0.8	13
30	Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer. Nature Communications, 2021, 12, 4753.	5.8	12
31	Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093248.	1.4	10
32	Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma. International Immunopharmacology, 2021, 96, 107610.	1.7	9
33	Identification of hub genes involved in the development of hepatocellular carcinoma by transcriptome sequencing. Oncotarget, 2017, 8, 60358-60367.	0.8	8
34	T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy. American Journal of Cancer Research, 2020, 10, 4585-4606.	1.4	8
35	A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer. Cancer Immunology, Immunotherapy, 2022, , 1.	2.0	8
36	Expression of p42.3 in non-small cell lung cancer. Annals of Translational Medicine, 2020, 8, 819-819.	0.7	7

#	Article	IF	Citations
37	Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 596573.	1.3	7
38	Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma. Journal of Cancer, 2021, 12, 1555-1562.	1.2	7
39	Genomic instability in lower-grade glioma: Prediction of prognosis based on lncRNA and immune infiltration. Molecular Therapy - Oncolytics, 2021, 22, 431-443.	2.0	6
40	Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. Frontiers in Oncology, 2022, 12, 785535.	1.3	6
41	Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 673248.	2.2	4
42	Differential genes and scoring criteria among immunogenomic clusters of lower-grade gliomas. International Immunopharmacology, 2021, 101, 108376.	1.7	4
43	Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 765-765.	0.7	3
44	Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease. Journal of Hepatology, 2021, 74, 1493-1494.	1.8	3
45	Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 709669.	1.8	3
46	CK20 and lymph node involvement predict adverse outcome of malignant intraductal papillary neoplasm of the bile duct. Histology and Histopathology, 2020, 35, 449-456.	0.5	2
47	Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma: A large real-world study from two centers.. Journal of Clinical Oncology, 2022, 40, e16155-e16155.	0.8	2
48	Association of chronic liver disease with the prognosis of COVID-19 patients. Journal of Hepatology, 2021, , .	1.8	1
49	eRNAs Identify Immune Microenvironment Patterns and Provide a Novel Prognostic Tool in Acute Myeloid Leukemia. Frontiers in Molecular Biosciences, 2022, 9, 877117.	1.6	1
50	Application of the Lung Immune Prognostic Index From Research to Clinical Practice. JAMA Oncology, 2020, 6, 299.	3.4	0
51	Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancer. JAMA Oncology, 2021, 7, 1248.	3.4	0
52	Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Genes. SSRN Electronic Journal, 0, , .	0.4	0
53	Lenvatinib Plus PD-1 Blockade in Refractory or Unresectable Biliary Tract Carcinoma: Insights from Real-World Evidences. SSRN Electronic Journal, 0, , .	0.4	0
54	Identification of TMB, CD8 T‐cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit‐toxicity ratio of anti‐PD‐1/PD‐L1 therapy. Clinical and Translational Medicine, 2021, 11, e598.	1.7	0

#	Article	IF	Citations
55	Genomic characterization and translational immunotherapy of microsatellite instability-high (MSI-H) in cholangiocarcinoma.. Journal of Clinical Oncology, 2022, 40, 4101-4101.	0.8	0